(c) to (e) Amount due in respect of some of the companies have already been worked cut and commuiiL cated to them. On$_e$ of the formulator, namely M/s. Fulford India Ltd. have already filed a writ petition against the notice of recovery in the Delhi High Court. The Writ Petition is listed for hearing on 9th September, 1985.

Statement

Sl. No.	Name of the Company	Date of issue of notice
	Doxycycline :	
1	M/s. Aristo Pharms.	24-5-1984
2	Dolphin Calcutta	24-5-1984
3	M/s. U.S. Vitamins	24-5-1984
4	M/s. IDPL	24-5-1984
5	M/s. Bengal Chemicals	24-5-1984
6	M/s. Biochem Pharmaceuticals	24-5-1984
7	Pharmaceuticals Co. of India	24-5-1984
8	M/s. Unique Pharms.	24-5-1984
	Gentamycin :	
9	M/s. Fulford India	31-5-1984
10	Nicholas Labs.	31-5-1984
11	Standard Pharmaceuticals	31-5-1984
12	Pharmaceuticals Co. of India	31-5-1984
13	M/s. Layka Labs.	31-5-1984
14	M/s. Biochem Pharmaceuticals	31-5-1984.

High Prices of antibiotics

231-5. SHRI BHAGATRAM MANHAR: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that the prices of certain antibiotic preparations such as Erythdoocin Tablets, Erythrocin Granules, Etrocin Tablets. Ampicillin Capsules, Lyramycin formulations, Klox capsules, Geramy-cin 'ormulations are very high;

(b) what is the price fixed for each formulation;

(c) what are the names of bulk, drugs on which these medicines are based and what is the quantity of each drug purchased by each company during the last four years, year-wise alongwith the price and name of seller;

(d) what are the names of the manufacturers of these medicines, their annual sales turn over and their gross and net profits during the last three years,, year-wise;

(e) whether these companies have any Associate Company, if so, the details thereof ; and

(f) whether any notice was issued to any of these companies under Drug Equalisation Account; and so. the details thereof indicating the name of the company, the items and amount of claim?

THE MINISTER OF CHEMICALS AND FERTILIZERS' (SHRi VEERENDRA PATIL): (a). to (f) Information the extent available would be collected and laid on the Table of the Rajya Sabha.

Profitability of drug companies

2316. SHRI BHAGATRAM MANHAR: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 774 given in the Rajya Sabha on the 25th March, 1985 and state:

(a) whether any study about pro fitability of the 47 drugs companies was made during the last three years;

(b) *i'* so, when and by whom; and if not. what are the reasons thereof;

(c) whether it is a fact that the profitability has gone up-

(d) if so, what was the pre-tax net profit, net worth the capital employed, the percentage of pre-tax profit to net worth an^ the sales turn over of formulations and bulk drugs of each company from 1979 to 1985; and

(e) what is the sales turn over of each Company in respect of Category I and II bulk drugs and formulations and what is the percentage to total sales turn over of formulations and bulk drugs of each company?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a), and (b) No, Sir. Government have not conducted any study of the profitability of 47 drugs companies referred to.

(c) To the extent information is available, the overall profitability norms fixed under Drugs (Price Con trol) Order, 1979 have not been exceeded.

(d) Does not arise.

(e) Details o" sale turnover category wise are not available.

Therapeutic group of Betamethasone

2317. SHRI (MOLANA) ASRARUL HAQ: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to refer to the answer to Unstarred Question 778 given in the Rajya Sabha on the 25th March 1985 and state:

(a) whether it is a fact that NDPDC has recommended Betamethasone under the Therapeutic group of Dermatological products;

(b) if so, whether it is a fact that Glaxo has the monopoly of formulations based on this drug;

(c). whether it is also a fact that this company has a major sale of formulations based on this drug for Asthama indication and other indications;

(d) what is the rationale for covering the drug only for Dermatological indication when the same is used for other indications having high sales turn over: and

(e) what was the sales turn ever of the formulations based on this drug of Glaxo indication-wise during the last three years, year-wise and in which form each is being marketed?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEER ENDRA PATIL): (a) and (d) Yes, Sir. Some of the builk drugs listed in the priority list drawn up by the Medical Experts oi the National Drugs & Pharmaceuticals Develop ment Council have multiple uses. Every such bulk drug has been classi fied under a major therapeutic group. The consensus of the National Drugs & Pharmaceuticals Development Council was that all the formulations based on priority drugs will be under price control irrespective of the therapeutic group under which the bulk drug is placed.

(b) M/s. Glaxo Laboratories (India) Limited are the major pro ducers of the formulations based en Betamethasone.

(c) and (e) The names of the for mulations based on Betamethasone and their sales turn over during the last three years have already been furnished in reply to Rajya Sabha Unstarred Question No. 778 answered on 25-3-1985. Details of sales of formulations by the company indi cation-wise are not monitored.

Fixation of price of Minaphillin

2318. SHRI (MOLANA) ASRARUL HAQ. Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) when and what price was fixed for Minaphillin Tablets and injections and what price of Theophil-lin and Etofyllin was taken in account while working the formulation price;